A Phase 1, Single-Blind, Randomized, Placebo-Controlled, Multiple Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of GS-6615 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 12 Nov 2013
Price : $35 *
At a glance
- Drugs Eleclazine (Primary)
- Indications Arrhythmias; Ischaemic heart disorders
- Focus Adverse reactions; Pharmacokinetics
- 01 Nov 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 17 Sep 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 10 May 2013 New trial record